NCT02529241View on ClinicalTrials.gov

An Open-label, Single Dose, Parallel Design, Phase 1 Clinical Study of LCB01-0371

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Healthy
Interventions
DRUG

Group 1:LCB01-0371

"1. Period:LCB01-0371 Tablet 400 mg~2. Period: LCB01-0371 Tablet 400 mg"

DRUG

Group 2:LCB01-0371

"1. Period:LCB01-0371 Tablet 800 mg~2. Period: LCB01-0371 Tablet 1200 mg"

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

LigaChem Biosciences, Inc.

INDUSTRY

NCT02529241 - An Open-label, Single Dose, Parallel Design, Phase 1 Clinical Study of LCB01-0371 | Biotech Hunter | Biotech Hunter